Longitudinal Health-Related Quality of Life Study among Cervical Cancer Patients Treated with Radiotherapy
Abstract
1. Introduction
2. Experimental Section
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sabulei, C.; Maree, J.E. An exploration into the quality of life of women treated for cervical cancer. Curationis 2019, 42, e1–e9. [Google Scholar] [CrossRef] [PubMed]
- Thapa, N.; Maharjan, M.; Xiong, Y. Impact of cervical cancer on quality of life of women in Hubei, China. Sci. Rep. 2018, 8, 11993. [Google Scholar] [CrossRef] [PubMed]
- Osann, K.; Hsieh, S.; Nelson, E.L.; Monk, B.J.; Chase, D.; Cella, D.; Wenzel, L. Factors associated with poor quality of life among cervical cancer survivors: Implications for clinical care and clinical trials. Gynecol. Oncol. 2014, 135, 266–272. [Google Scholar] [CrossRef] [PubMed]
- Pfaendler, K.S.; Wenzel, L.; Mechanic, M.B.; Penner, K.R. Cervical cancer survivorship: Long-term quality of life and social support. Clin. Ther. 2015, 37, 39–48. [Google Scholar] [CrossRef] [PubMed]
- Didkowska, J.; Wojciechowska, U. Illnesses and Deaths from Malignant Neoplasms in Poland. National Cancer Registry. National Oncology Institute Maria Sklodowska Curie-National Research Institute. Available online: http://onkologia.org.pl/k/epidemiologia (accessed on 20 October 2020).
- Aaronson, N.K.; Ahmedzai, S.; Bergman, B.; Bullinger, M.; Cull, A.; Duez, N.J.; Filiberti, A.; Flechtner, H.; Fleishman, S.B.; de Haes, J.C.; et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993, 85, 365–376. [Google Scholar] [CrossRef] [PubMed]
- Paradowska, D.; Tomaszewski, K.A.; Bałajewicz-Nowak, M.; Bereza, K.; Tomaszewska, I.M.; Paradowski, J.; Pityński, K.; Skotnicki, P.; Greimel, E.R.; Bottomley, A. Validation of the Polish version of the EORTC QLQ-CX24 module for the assessment of health-related quality of life in women with cervical cancer. Eur. J. Cancer Care (Engl.) 2014, 23, 214–220. [Google Scholar] [CrossRef] [PubMed]
- Bashir, A.; Kumar, D.; Dewan, D.; Sharma, R. A longitudinal study to assess quality of life in cervical cancer patients before and after cancer directed treatment. Int. J. Med. Sci. Public Health 2017, 6, 1626–1634. [Google Scholar] [CrossRef]
- Fleming, N.D.; Ramirez, P.T.; Soliman, P.T.; Schmeler, K.M.; Chisholm, G.B.; Nick, A.M.; Westin, S.N.; Frumovitz, M. Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation. Gynecol. Oncol. 2016, 143, 596–603. [Google Scholar] [CrossRef] [PubMed]
- Dos Santos, L.N.; Castaneda, L.; de Aguiar, S.S.; Thuler, L.C.S.; Koifman, R.J.; Bergmann, A. Health-related Quality of Life in Women with Cervical Cancer. Rev. Bras Ginecol. Obstet. 2019, 41, 242–248. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, M.E.; Wiskemann, J.; Steindorf, K. Quality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis. Qual. Life Res. 2018, 27, 2077–2086. [Google Scholar] [CrossRef] [PubMed]
- Grion, R.C.; Baccaro, L.F.; Vaz, A.F.; Costa-Paiva, L.; Conde, D.M.; Pinto-Neto, A.M. Sexual function and quality of life in women with cervical cancer before radiotherapy: A pilot study. Arch. Gynecol. Obstet. 2016, 293, 879–886. [Google Scholar] [CrossRef] [PubMed]
- Bjelic-Radisic, V.; Jensen, P.T.; Vlasic, K.K.; Waldenstrom, A.C.; Singer, S.; Chie, W.; Nordin, A.; Greimel, E. Quality of life characteristics inpatients with cervical cancer. Eur. J. Cancer 2012, 48, 3009–3018. [Google Scholar] [CrossRef] [PubMed]
- Bae, H.; Park, H. Sexual function, depression, and quality of life in patients with cervical cancer. Support Care Cancer 2016, 24, 1277–1283. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.; Lim, M.C.; Kim, S.I.; Joo, J.; Lee, D.O.; Park, S.Y. Comparison of Quality of Life and Sexuality between Cervical Cancer Survivors and Healthy Women. Cancer Res. Treat. 2016, 48, 1321–1329. [Google Scholar] [CrossRef] [PubMed]
- Huang, H.Y.; Tsai, W.C.; Chou, W.Y. Quality of life of breast and cervical cancer survivors. BMC Women Health 2017, 17, 30. [Google Scholar] [CrossRef] [PubMed]
- Ferrandina, G.; Mantegna, G.; Petrillo, M. Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: A prospective, longitudinal study. Gynecol. Oncol. 2012, 124, 389–394. [Google Scholar] [CrossRef] [PubMed]
- Pasek, M.; Suchocka, L.; Urbański, K. Quality of life in cervical cancer patients treated with radiation therapy. J. Clin. Nurs. 2013, 22, 690–697. [Google Scholar] [CrossRef] [PubMed]
- Singh, U.; Verma, M.L.; Rahman, Z.; Qureshi, S.; Srivastava, K. Factors affecting quality of life of cervical cancer patients: A multivariate analysis. J. Cancer Res. Ther. 2019, 15, 338–344. [Google Scholar]
- Rahman, Z.; Singh, U.; Qureshi, S.; Nisha Srivastav, K.; Nishchal, A. Assessment of Quality of Life in Treated Patients of Cancer Cervix. J. Midlife Health 2017, 8, 183–188. [Google Scholar] [PubMed]
- Prasongvej, P.; Nanthakomon, T.; Jaisin, K. Quality of Life in Cervical Cancer Survivors and Healthy Women: Thai Urban Population Study. Asian Pac. J. Cancer Prev. 2017, 18, 385–389. [Google Scholar] [PubMed]
n Respondents | % Respondents | |
---|---|---|
Marital status | ||
Single | 2 | 4.1 |
Married | 36 | 73.5 |
Divorced | 2 | 4.1 |
Widow | 8 | 16.3 |
Informal relationship | 1 | 2.0 |
Education | ||
Primary | 12 | 24.5 |
Professional | 15 | 30.6 |
Secondary | 17 | 34.7 |
Higher | 5 | 10.2 |
Distance from home to cancer center | ||
Up to 5 km | 3 | 6.1 |
6–15 m | 0 | 0.0 |
16–30 km | 2 | 4.1 |
31–45 km | 4 | 8.2 |
Over 45 km | 40 | 81.6 |
Source of income | ||
Work | 15 | 30.6 |
Benefit | 13 | 26.5 |
Pension | 8 | 16.3 |
Welfare | 3 | 6.1 |
Other | 10 | 20.4 |
n Respondents | % Respondents | |
---|---|---|
Histology | ||
Planoepitheliale | 44 | 89.8 |
Infiltratio carcinomatosa | 5 | 10.2 |
Stage | ||
IB | 4 | 8.2 |
IIA | 7 | 14.3 |
IIB | 4 | 8.2 |
IIIB | 25 | 51.0 |
IVA | 1 | 2.0 |
No data | 8 | 16.3 |
No. of radiotherapy sessions | ||
22–24 | 12 | 24.5 |
25–27 | 31 | 63.3 |
28–32 | 6 | 12.2 |
Irradiation dose (Gy) | ||
44–46 | 10 | 20.4 |
48–50 | 21 | 42.8 |
52–56 | 18 | 35.8 |
Chemotherapy | ||
No | 14 | 28.6 |
Yes | 35 | 71.4 |
Surgical cancer treatment | ||
No | 36 | 73.5 |
Yes | 13 | 26.5 |
49 | 100% |
Variable | Stage of Study | N Valid | Mean | SD | Min | Max | Lower Quartile | Upper Quartile | Quartile Interval | Sć Skew | Standard Skew Error |
---|---|---|---|---|---|---|---|---|---|---|---|
Overall health | I | 49 | 4.53 | 1.54 | 1.00000 | 7.0000 | 4.00000 | 5.0000 | 1.00000 | −0.14864 | 0.339828 |
II | 49 | 4.71 | 1.29 | 2.00000 | 7.0000 | 4.00000 | 6.0000 | 2.00000 | 0.32014 | 0.339828 | |
III | 49 | 4.71 | 1.46 | 1.00000 | 7.0000 | 4.00000 | 6.0000 | 2.00000 | −0.19232 | 0.339828 | |
IV | 49 | 4.43 | 1.68 | 1.00000 | 7.0000 | 3.00000 | 6.0000 | 3.00000 | −0.00781 | 0.339828 | |
Quality of life | I | 49 | 4.76 | 1.55 | 1.00000 | 7.0000 | 4.00000 | 6.0000 | 2.00000 | −0.27357 | 0.339828 |
II | 49 | 4.76 | 1.28 | 2.00000 | 7.0000 | 4.00000 | 6.0000 | 2.00000 | 0.11102 | 0.339828 | |
III | 49 | 4.78 | 1.52 | 1.00000 | 7.0000 | 4.00000 | 6.0000 | 2.00000 | −0.83295 | 0.339828 | |
IV | 49 | 4.51 | 1.71 | 1.00000 | 7.0000 | 3.00000 | 6.0000 | 3.00000 | −0.14860 | 0.339828 |
Before Treatment | Directly after Treatment | 5–6 Months after Treatment | 5 Years after Treatment | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | Median | SD | Min. | Max | Mean | Median | SD | Min. | Max | Mean | Median | SD | Min. | Max | Mean | Median | SD | Min. | Max | |
Global health status/ QoL (standardized) | 60.71 | 66.67 | 25.17 | 0.00 | 100.00 | 62.24 | 58.33 | 20.91 | 25.00 | 100.00 | 62.41 | 66.67 | 23.58 | 0.00 | 100.00 | 57.82 | 50.00 | 26.97 | 0.00 | 100.00 |
before Treatment | Rank | Directly after Treatment | Rank | 5–6 Months after Treatment | Rank | 5 Years after Treatment | Rank | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | Median | SD | Min. | Max | Mean | Median | SD | Min. | Max | Mean | Median | SD | Min. | Max | Mean | Median | SD | Min. | Max | |||||
Physical functioning (PF) | 76.33 | 80.00 | 18.16 | 26.67 | 100.00 | 1 | 67.48 | 73.33 | 18.74 | 26.67 | 100.00 | 2 | 67.35 | 73.33 | 21.74 | 6.67 | 100.00 | 4 | 62.86 | 66.67 | 22.73 | 20.00 | 100.00 | 4 |
Role functioning (RF) | 75.85 | 83.33 | 27.23 | 0.00 | 100.00 | 2 | 56.46 | 50.00 | 30.01 | 0.00 | 100.00 | 5 | 73.81 | 83.33 | 29.66 | 0.00 | 100.00 | 2 | 69.73 | 66.67 | 28.60 | 0.00 | 100.00 | 2 |
Emotional functioning (EF) | 52.38 | 58.33 | 26.02 | 0.00 | 100.00 | 5 | 60.37 | 66.67 | 23.73 | 0.00 | 100.00 | 4 | 59.69 | 66.67 | 21.41 | 8.33 | 100.00 | 5 | 54.08 | 58.33 | 27.17 | 0.00 | 100.00 | 5 |
Memory and concentration (CF) | 71.09 | 66.67 | 26.08 | 0.00 | 100.00 | 4 | 68.71 | 66.67 | 25.83 | 0.00 | 100.00 | 1 | 68.37 | 66.67 | 28.10 | 0.00 | 100.00 | 3 | 68.37 | 66.67 | 26.84 | 0.00 | 100.00 | 3 |
Social functioning (SF) | 73.47 | 83.33 | 31.17 | 0.00 | 100.00 | 3 | 67.01 | 66.67 | 28.77 | 0.00 | 100.00 | 3 | 80.61 | 83.33 | 23.41 | 0.00 | 100.00 | 1 | 73.81 | 66.67 | 24.30 | 0.00 | 100.00 | 1 |
Financial impact of the disease (FI) | 44.90 | 33.33 | 32.31 | 0.00 | 100.00 | 6 | 46.94 | 33.33 | 30.37 | 0.00 | 100.00 | 6 | 46.94 | 33.33 | 27.99 | 0.00 | 100.00 | 6 | 41.50 | 33.33 | 36.98 | 0.00 | 100.00 | 6 |
before Treatment | Rank | Directly after Treatment | Rank | 5–6 Months after Treatment | Rank | 5 Years after Treatment | Rank | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | Median | SD | Min. | Max | Mean | Median | SD | Min. | Max | Mean | Median | SD | Min. | Max | Mean | Median | SD | Min. | Max | |||||
Fatigue (FA) | 37.87 | 3333 | 23.34 | 0.00 | 100.00 | 2 | 43.54 | 33.33 | 23.88 | 0.00 | 100.00 | 2 | 45.35 | 33.33 | 22.32 | 0.00 | 100.00 | 1 | 48.07 | 44.44 | 22.84 | 0.00 | 100.00 | 2 |
Nausea and vomiting (NV) | 7.48 | 0.00 | 12.30 | 0.00 | 50.00 | 8 | 21.43 | 16.67 | 23.32 | 0.00 | 83.33 | 7 | 9.52 | 0.00 | 14.03 | 0.00 | 50.00 | 8 | 13.27 | 0.00 | 18.94 | 0.00 | 66.67 | 7 |
Pain (PA) | 29.25 | 33.33 | 25.80 | 0.00 | 100.00 | 3 | 29.93 | 33.33 | 24.76 | 0.00 | 83.33 | 5 | 30.61 | 33.33 | 24.14 | 0.00 | 100.00 | 3 | 37.76 | 33.33 | 29.22 | 0.00 | 100.00 | 3 |
Dyspnea (DY) | 14.29 | 0.00 | 21.52 | 0.00 | 100.00 | 6 | 18.37 | 0.00 | 23.63 | 0.00 | 100.00 | 8 | 23.81 | 0.00 | 28.87 | 0.00 | 100.00 | 4 | 27.21 | 33.33 | 27.78 | 0.00 | 100.00 | 5 |
Insomnia (SL) | 44.22 | 33.33 | 31.47 | 0.00 | 100.00 | 1 | 46.94 | 33.33 | 32.57 | 0.00 | 100.00 | 1 | 42.18 | 33.33 | 31.01 | 0.00 | 100.00 | 2 | 51.70 | 33.33 | 35.40 | 0.00 | 100.00 | 1 |
Loss of appetite (AP) | 16.33 | 0.00 | 26.46 | 0.00 | 100.00 | 5 | 43.54 | 33.33 | 30.58 | 0.00 | 100.00 | 2 | 17.69 | 0.00 | 21.63 | 0.00 | 100.00 | 6 | 23.81 | 33.33 | 28.05 | 0.00 | 100.00 | 6 |
Constipation (CO) | 28.57 | 33.33 | 29.66 | 0.00 | 100.00 | 4 | 26.53 | 33.33 | 25.44 | 0.00 | 100.00 | 6 | 15.65 | 0.00 | 22.67 | 0.00 | 100.00 | 7 | 21.09 | 0.00 | 29.42 | 0.00 | 100.00 | 8 |
Diarrhea (DI) | 11.56 | 0.00 | 17.42 | 0.00 | 66.67 | 7 | 31.97 | 33.33 | 28.02 | 0.00 | 100.00 | 4 | 23.13 | 33.33 | 23.77 | 0.00 | 66.67 | 5 | 37.41 | 33.33 | 32.37 | 0.00 | 100.00 | 4 |
Stage I | Stage II | Stage III | Stage IV | ANOVA with Secondary Measurement | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
M | sd | M | sd | M | sd | M | sd | F | df | p | η2 | |
PF | 76.33 | 18.16 | 67.48 | 18.74 | 67.35 | 21.74 | 62.86 | 22.73 | 8.29 | 3.144 | 0.000 *** | 0.147 |
RF | 75.85 | 27.23 | 56.46 | 30.01 | 73.81 | 29.66 | 69.73 | 28.60 | 6.73 | 3.144 | 0.000 *** | 0.123 |
EF | 52.38 | 26.02 | 60.37 | 23.73 | 59.69 | 21.41 | 54.08 | 27.17 | 2.75 | 3.144 | 0.045 * | 0.054 |
CF | 71.09 | 26.08 | 68.71 | 25.83 | 68.37 | 28.10 | 68.37 | 26.84 | 0.30 | 3.144 | 0.826 | 0.006 |
SF | 73.47 | 31.17 | 67.01 | 28.77 | 80.61 | 23.41 | 73.81 | 24.30 | 2.72 | 3.144 | 0.046 * | 0.054 |
FA a | 37.87 | 23.34 | 43.54 | 23.88 | 45.35 | 22.32 | 48.07 | 22.84 | 3.39 | 3.123 | 0.026 * | 0.066 |
NV a | 7.48 | 12.30 | 21.43 | 23.32 | 9.52 | 14.03 | 13.27 | 18.94 | 8.83 | 2.111 | 0.000 *** | 0.155 |
PA | 29.25 | 25.80 | 29.93 | 24.76 | 30.61 | 24.14 | 37.76 | 29.22 | 1.72 | 3.144 | 0.165 | 0.035 |
DY | 14.29 | 21.52 | 18.37 | 23.63 | 23.81 | 28.87 | 27.21 | 27.78 | 4.97 | 3.144 | 0.003 ** | 0.094 |
SL | 44.22 | 31.47 | 46.94 | 32.57 | 42.18 | 31.01 | 51.70 | 35.40 | 1.25 | 3.144 | 0.294 | 0.025 |
AP | 16.33 | 26.46 | 43.54 | 30.58 | 17.69 | 21.63 | 23.81 | 28.05 | 15.93 | 3.144 | 0.000 *** | 0.249 |
CO a | 28.57 | 29.66 | 26.53 | 25.44 | 15.65 | 22.67 | 21.09 | 29.42 | 3.36 | 3.122 | 0.027 * | 0.065 |
DI a | 11.56 | 17.42 | 31.97 | 28.02 | 23.13 | 23.77 | 37.41 | 32.37 | 11.67 | 3.121 | 0.000 *** | 0.196 |
FI | 44.90 | 32.31 | 46.94 | 30.37 | 46.94 | 27.99 | 41.50 | 36.98 | 0.53 | 3.144 | 0.664 | 0.011 |
SI-SII | SI-SIII | SI-SIV | SII-SIII | SII-SIV | SIII-SIV | |
---|---|---|---|---|---|---|
PF | 0.003 ** | 0.013 * | 0.000 *** | 0.999 | 0.844 | 0.594 |
RF | 0.001 *** | 0.999 | 0.999 | 0.004 ** | 0.087 | 0.999 |
EF | 0.166 | 0.146 | 0.999 | 0.999 | 0.748 | 0.431 |
SF | 0.999 | 0.780 | 0.999 | 0.067 | 0.999 | 0.490 |
FA | 0.666 | 0.327 | 0.060 | 0.999 | 0.944 | 0.999 |
NV | 0.001 *** | 0.999 | 0.184 | 0.003 ** | 0.153 | 0.882 |
DY | 0.999 | 0.071 | 0.005 ** | 0.618 | 0.132 | 0.999 |
AP | 0.000 *** | 0.999 | 0.656 | 0.000 *** | 0.003 ** | 0.709 |
CO | 0.999 | 0.071 | 0.882 | 0.116 | 0.999 | 0.618 |
DI | 0.000 *** | 0.004 ** | 0.000 *** | 0.342 | 0.999 | 0.053 |
Statistics | Before Treatment | Directly after Treatment | 5–6 Months after Treatment | 5 Years after Treatment | ||||
---|---|---|---|---|---|---|---|---|
Anxiety | Depression | Anxiety | Depression | Anxiety | Depression | Anxiety | Depression | |
Mean | 8.49 | 5.76 | 7.35 | 5.45 | 7.78 | 5.02 | 8.12 | 5.69 |
Median | 8 | 5 | 7 | 5 | 7 | 4 | 8 | 6 |
SD | 4.84 | 440 | 4.01 | 3.83 | 4.55 | 4.08 | 4.65 | 4.31 |
Min | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Max | 19 | 19 | 16 | 13 | 18 | 13 | 18 | 14 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pasek, M.; Suchocka, L.; Osuch-Pęcak, G.; Muzykiewicz, K.; Iwańska, E.; Kaducakowa, H.; Goździalska, A.; Goździalska, M. Longitudinal Health-Related Quality of Life Study among Cervical Cancer Patients Treated with Radiotherapy. J. Clin. Med. 2021, 10, 226. https://doi.org/10.3390/jcm10020226
Pasek M, Suchocka L, Osuch-Pęcak G, Muzykiewicz K, Iwańska E, Kaducakowa H, Goździalska A, Goździalska M. Longitudinal Health-Related Quality of Life Study among Cervical Cancer Patients Treated with Radiotherapy. Journal of Clinical Medicine. 2021; 10(2):226. https://doi.org/10.3390/jcm10020226
Chicago/Turabian StylePasek, Małgorzata, Lilia Suchocka, Grażyna Osuch-Pęcak, Konrad Muzykiewicz, Ewa Iwańska, Helena Kaducakowa, Anna Goździalska, and Magdalena Goździalska. 2021. "Longitudinal Health-Related Quality of Life Study among Cervical Cancer Patients Treated with Radiotherapy" Journal of Clinical Medicine 10, no. 2: 226. https://doi.org/10.3390/jcm10020226
APA StylePasek, M., Suchocka, L., Osuch-Pęcak, G., Muzykiewicz, K., Iwańska, E., Kaducakowa, H., Goździalska, A., & Goździalska, M. (2021). Longitudinal Health-Related Quality of Life Study among Cervical Cancer Patients Treated with Radiotherapy. Journal of Clinical Medicine, 10(2), 226. https://doi.org/10.3390/jcm10020226